20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T15424 | GSK1379725A | Epigenetic Reader Domain | |
GSK1379725A is a selective BPTF ligand (Kd: 2.8 uM). It also shows no binding activity for Brd4. | |||
T2072 | BET bromodomain inhibitor | Epigenetic Reader Domain | |
BET bromodomain inhibitor is a potent BET inhibitor. | |||
T11925 | M‑89 | Epigenetic Reader Domain , Histone Methyltransferase | |
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia... | |||
T5440 | Dbet57 | Epigenetic Reader Domain | |
dBET57 is heterobifunctional degrader of BRD4 based on the PROTAC technology, exhibits significant degradation of BRD4BD1 with a DC50/5h of 500 nM ,and inactive on BRD4BD2 | |||
T4495 | DBET1 | Epigenetic Reader Domain | |
dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. It induces cereblon-dependent BET protein degradation in vitro (EC50: 430 nM) and induces apoptosis. | |||
T5130 | DBET6 | Apoptosis , Epigenetic Reader Domain | |
dBET6 is a selective and cell-permeable degrader of BET based on PROTAC (IC50: 14 nM). It has antitumor activity. | |||
T6783 | BI-7273 | Epigenetic Reader Domain | |
BI-7273 is an effective, specific, BRD9 BD Inhibitor, which can infiltrate cell. | |||
TQ0083 | NI-57 | Epigenetic Reader Domain | |
NI-57 is an inhibitor of proteins of bromodomain and plant homeodomain finger-containing (BRPF) family, with IC50s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively. | |||
TQ0253 | PLX51107 | Epigenetic Reader Domain | |
PLX51107 is a potent and selective BET inhibitor (Kds: 1.6, 2.1, 1.7, and 5 nM for BRD2-BD1, BRD3-BD1, BRD4-BD1, and BRDT-BD1). | |||
T12112 | MS402 | Epigenetic Reader Domain | |
MS402 is a novel BD1-selective BET BrD inhibitor. | |||
TQ0069 | MI-503 | Epigenetic Reader Domain , Histone Methyltransferase | |
MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction. | |||
T16321 | NI-42 | Epigenetic Reader Domain | |
NI-42 is a structurally orthogonal chemical probe for the BRPFs and is biased. It effective inhibitor of the BRD of the BRPFs (IC50s of BRPF1/2/3=7.9/48/260 nM; Kds of BRPF1/2/3=40/210/940 nM). It also has excellent sele... | |||
T9749 | FHD-286 | Epigenetic Reader Domain | |
FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia. | |||
T2127 | OF-1 | Epigenetic Reader Domain | |
OF-1 is a potent inhibitor of BRPF1B and BRPF2 bromodomain. | |||
T19935 | XD14 | Epigenetic Reader Domain | |
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively). | |||
T3973 | PF-CBP1 | Epigenetic Reader Domain | |
PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP). It inhibits CREBBP (IC50: 125 nM) and p300 bromodomains (IC50: 363 nM). | |||
T14685 | BMS-986158 | Epigenetic Reader Domain | |
BMS-986158 is a highly effective BET inhibitor, demonstrating IC50 values of 6.6 nM in NCI-H211 small cell lung cancer (SCLC) cells and 5 nM in MDA-MB231 triple negative breast cancer (TNBC) cells. | |||
T13363 | Y06137 | Epigenetic Reader Domain , PKC | |
Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer. | |||
T3311 | GSK6853 | Epigenetic Reader Domain | |
GSK6853 is a potent, soluble, cell-active, and highly selective inhibitor of the BRPF1 bromodomain. | |||
TQ0058 | MI-463 | Epigenetic Reader Domain , Histone Methyltransferase | |
MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM). |